Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross SD Zilbrysq Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.05.37

    Zilbrysq (zilucoplan) Coverage for Generalized Myasthenia Gravis

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.05.37 alerts

    Get alerted when Policy 05.05.37 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of Zilbrysq (zilucoplan) for adult members with acetylcholine receptor antibody-positive generalized myasthenia gravis. Coverage requires the applicable clinical criteria, documentation, dosing limits, and continuation requirements to be met.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyZilbrysq (zilucoplan) Coverage for Generalized Myasthenia Gravis
    Policy CodePolicy 05.05.37
    Change TypeNo material change
    Effective DateJan 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of antibody status, disease classification, MG-ADL score, relevant prior therapies, and treatment response history with initial prior authorization requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 moInitial authorization duration
    12 moContinuation authorization duration
    ≥6Minimum MG-ADL score for initial approval
    2 / ≥1 yrRequired failed immunosuppressive therapies

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3 dosesFDA-recommended weight-based daily doses

    Coverage Criteria

    Initial Therapy

    Covered for initial treatment when all of the following criteria are met, including one of the prior-treatment-failure pathways.

    Initial approval

    • Clinical criteria

      • The member is anti-acetylcholine receptor (AChR) antibody positive; has Myasthenia Gravis Foundation of America (MGFA) clinical classification II to IV; and has an MG activities of daily living (MG-ADL) total score of at least 6.AChR positive; MGFA II-IV; MG-ADL ≥6
    • ONE of the following prior-treatment-failure pathways

      • Immunosuppressive therapy pathway

        • The member has failed treatment over at least one year with at least two immunosuppressive therapies.At least 2 therapies over ≥1 year

          Examples include azathioprine, cyclosporine, mycophenolate, tacrolimus, methotrexate, cyclophosphamide, and rituximab.

      • Plasmapheresis, plasma exchange, or IVIG pathway

        • The member has failed at least one immunosuppressive therapy and required chronic plasmapheresis, plasma exchange (PE), or intravenous immunoglobulin (IVIG).At least 1 immunosuppressive therapy plus chronic plasmapheresis, PE, or IVIG
    • Prior advanced therapy response

      • The member has a documented inadequate response to Rystiggo, Vyvgart, Vyvgart Hytrulo, eculizumab, or Ultomiris.Documented inadequate response
    • Concomitant therapy restriction

      • The member will not use Zilbrysq concomitantly with eculizumab, Ultomiris, Rystiggo, Vyvgart, Vyvgart Hytrulo, IVIG, or rituximab for the same indication.No prohibited concomitant therapy

    Continuation Therapy

    Covered for continuation when all of the following criteria are met.

    Continuation approval

    • There is no evidence of unacceptable toxicity or disease progression while the member is on the current regimen, and the member demonstrates a positive response to therapy.Positive response with no unacceptable toxicity or disease progression

      Examples of positive response include improvement in the MG-ADL score or changes from baseline in the Quantitative Myasthenia Gravis (QMG) total score.

    Non-Formulary Exception

    Non-formulary exception coverage requires that the approval criteria be met plus all of the following requirements.

    Non-formulary exception requirements

    • The requested drug is used for an FDA-approved indication or an indication supported by compendia of current literature, such as AHFS, Micromedex, or current accepted guidelines.

      Diagnostic testing or laboratory results are required when applicable.

    • The prescribed dose and quantity fall within FDA-approved labeling or dosing guidelines found in compendia of current literature.
    • All covered formulary alternatives on any tier will be ineffective, have been ineffective, would not be as effective as the non-formulary drug, or would cause adverse effects.

      Documentation must include prior treatment failure, adverse-event severity when applicable, prior dosage and duration, or contraindication to formulary alternatives.

    Zilbrysq must not be used concomitantly with eculizumab, Ultomiris, Rystiggo, Vyvgart, Vyvgart Hytrulo, intravenous immune globulin (IVIG), or rituximab when these therapies are used for the same indication.

    Zilbrysq is considered not medically necessary when the member does not meet the coverage criteria established in this policy.

    Initial Therapy Criteria

    Initial Therapy for Generalized Myasthenia Gravis

    Authorization of 6 months may be granted for initial treatment of generalized myasthenia gravis when all of the following criteria are met.

    Initial therapy for generalized myasthenia gravis

    • The member is anti-acetylcholine receptor (AChR) antibody positive.AChR antibody positive
    • The member has Myasthenia Gravis Foundation of America (MGFA) clinical classification II to IV.MGFA II-IV
    • The member has an MG activities of daily living (MG-ADL) total score of at least 6.MG-ADL ≥6
    • ONE of the following prior-treatment-failure pathways

    Continuation Criteria

    Continuation Therapy

    Authorization of 12 months may be granted for continued treatment when all of the following criteria are met.

    Continuation therapy

    • There is no evidence of unacceptable toxicity or disease progression while the member is on the current regimen, and the member demonstrates a positive response to therapy.Positive response with no unacceptable toxicity or disease progression

      Examples of positive response include improvement in the MG-ADL score or changes from baseline in the Quantitative Myasthenia Gravis (QMG) total score.

    Prior Treatment Requirements

    StepRequirementPrior treatment failure
    1Before initial Zilbrysq authorizationDocumented failure of either at least two immunosuppressive therapies over at least one year, or at least one immunosuppressive therapy with chronic plasmapheresis, plasma exchange, or intravenous immunoglobulin (IVIG).

    Dosing and Quantity Limits

    Quantity limit
    MedicationZilbrysq (zilucoplan) 16.6 mg/0.416 mL prefilled syringe
    AdministrationSubcutaneous administration once daily
    Quantity limit1 syringe per day
    Quantity limit
    MedicationZilbrysq (zilucoplan) 23 mg/0.574 mL prefilled syringe
    Weight rangeMembers weighing ≥56 to <77 kg
    Daily dose23 mg subcutaneously once daily

    Clinical and Dosing Parameters

    MG-ADL score
    MeasureMyasthenia Gravis activities of daily living (MG-ADL) total score
    Required threshold≥6
    Coverage applicationRequired for initial treatment authorization
    MGFA clinical classification
    Classification systemMyasthenia Gravis Foundation of America (MGFA) clinical classification
    Qualifying rangeClass II to IV
    Coverage applicationRequired for initial treatment authorization

    Authorization and Documentation Guidance

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for initial Zilbrysq treatment of generalized myasthenia gravis (gMG). Authorization may be granted for 6 months when all applicable clinical criteria are met.

    • Positive anti-acetylcholine receptor (AChR) antibody test.
    • Myasthenia Gravis Foundation of America (MGFA) clinical classification II–IV.
    • MG activities of daily living (MGADL) total score ≥6.
    • Required treatment-failure criteria and inadequate response to specified advanced therapies must be documented.
    • Zilbrysq will not be used concomitantly for the same indication with eculizumab, Ultomiris, Rystiggo, Vyvgart, Vyvgart Hytrulo, intravenous immune globulin (IVIG), or rituximab.
    Prior Authorization

    Continuation Prior Authorization

    Reauthorization requires prior approval for continued Zilbrysq treatment. Authorization may be granted for 12 months when the member demonstrates ongoing benefit on the current regimen without unacceptable toxicity or disease progression.

    Policy Background

    This policy addresses coverage of Zilbrysq (zilucoplan) for adult patients with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis. Initial coverage is limited to members with MGFA clinical classification II to IV, an MG-ADL total score of at least 6, and the required inadequate response to prior therapies. Continued coverage requires documented clinical benefit without unacceptable toxicity or disease progression.

    Clinical Definitions

    Covered FDA-approved indication
    MedicationZilbrysq (zilucoplan)
    IndicationTreatment of generalized myasthenia gravis (gMG)
    Eligible patientsAdult patients who are acetylcholine receptor (AChR) antibody positive
    MGFA clinical classification requirement
    Classification systemMyasthenia Gravis Foundation of America (MGFA) clinical classification
    Qualifying rangeII to IV
    Coverage applicationRequired as part of the initial generalized myasthenia gravis criteria
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyZilbrysq (zilucoplan) Coverage for Generalized Myasthenia Gravis
    Policy CodePolicy 05.05.37
    Change TypeNo material change
    Effective DateJan 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of antibody status, disease classification, MG-ADL score, relevant prior therapies, and treatment response history with initial prior authorization requests.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation CriteriaPrior Treatment RequirementsDosing and Quantity LimitsClinical and Dosing ParametersAuthorization and Documentation GuidancePolicy BackgroundClinical Definitions
    • The member has failed treatment over at least one year with at least two immunosuppressive therapies.At least 2 therapies over ≥1 year

      Examples include azathioprine, cyclosporine, mycophenolate, tacrolimus, methotrexate, cyclophosphamide, and rituximab.

    • The member has failed at least one immunosuppressive therapy and required chronic plasmapheresis, plasma exchange (PE), or intravenous immunoglobulin (IVIG).At least 1 immunosuppressive therapy plus chronic plasmapheresis, PE, or IVIG
  1. The member has a documented inadequate response to Rystiggo, Vyvgart, Vyvgart Hytrulo, eculizumab, or Ultomiris.Documented inadequate response
  2. The member will not use Zilbrysq concomitantly with eculizumab, Ultomiris, Rystiggo, Vyvgart, Vyvgart Hytrulo, IVIG, or rituximab for the same indication.No prohibited concomitant therapy
  3. Quantity limit
    MedicationZilbrysq (zilucoplan) 32.4 mg/0.81 mL prefilled syringe
    Weight rangeMembers weighing ≥77 kg
    Quantity limit1 syringe per day
    Daily dose32.4 mg subcutaneously once daily
    Weight-based dose
    MedicationZilbrysq (zilucoplan)
    Weight rangeMembers weighing <56 kg
    Daily dose16.6 mg subcutaneously once daily
    Prior immunosuppressive therapy
    Therapy typeImmunosuppressive therapy
    Minimum durationAt least one year
    Initial treatment pathwayFailure of at least two immunosuppressive therapies over at least one year
    Zilbrysq dose by actual body weight
    Weight <56 kg16.6 mg subcutaneously once daily
    Weight ≥56 to <77 kg23 mg subcutaneously once daily
    Weight ≥77 kg32.4 mg subcutaneously once daily
    • Document a positive clinical response, such as improvement in MG-ADL score or change from baseline in Quantitative Myasthenia Gravis (QMG) total score.
    • Document no evidence of unacceptable toxicity.
    • Document no evidence of disease progression while receiving the current regimen.
    Prior Authorization

    Non-Formulary Exception Approval

    For a non-formulary product, the request must satisfy the applicable gMG approval criteria and all Non-Formulary Exception Criteria before coverage can be approved.

    • The requested drug must be used for an FDA-approved indication or an indication supported by current compendia or accepted clinical guidelines; include diagnostic testing or laboratory results when applicable.
    • The prescribed dose and quantity must be within FDA-approved labeling or compendia dosing guidance.
    • Covered formulary alternatives on any tier must be ineffective, previously ineffective, less effective, associated with adverse effects, or contraindicated.
    Step Therapy

    Failure of Specified Advanced Therapies

    Document an inadequate response to at least one of the specified advanced therapies before requesting Zilbrysq for gMG.

    • Rystiggo.
    • Vyvgart.
    • Vyvgart Hytrulo.
    • Eculizumab.
    • Ultomiris.
    Step Therapy

    Prior Immunosuppressive Therapy Failure

    Document the required prior immunosuppressive-treatment failure pathway. The member must have failed treatment over at least one year with at least two immunosuppressive therapies, or failed at least one immunosuppressive therapy and required chronic plasmapheresis, plasma exchange (PE), or intravenous immunoglobulin (IVIG).

    • Examples of immunosuppressive therapies include azathioprine, cyclosporine, mycophenolate, tacrolimus, methotrexate, cyclophosphamide, and rituximab.
    • Alternative qualifying pathway: failure of at least one immunosuppressive therapy plus chronic plasmapheresis, PE, or IVIG.
    Documentation Required

    Initial Request Documentation

    Include records supporting the initial request when submitting the prior authorization. Chart notes, medical records, or claims history must substantiate the diagnosis and prior treatment history.

    • Positive AChR antibody test.
    • MGFA clinical classification score.
    • MGADL score.
    • Previous IVIG use, if applicable.
    • Prior immunosuppressive therapies.
    • Prior chronic plasmapheresis or plasma exchange, if applicable.
    Documentation Required

    Continuation Request Documentation

    Include chart notes or medical record documentation supporting a positive clinical response to Zilbrysq with each continuation request.

    • Document improvement in MG-ADL score and/or changes from baseline in QMG total score when available.
    • Documentation must also support continued tolerability and absence of disease progression.
    Documentation Required

    Non-Formulary Exception Documentation

    For a non-formulary exception, submit documentation showing that covered formulary alternatives are unsuitable for the member.

    • Chart notes or other records documenting prior treatment failure, including dosage and duration.
    • For adverse effects, document the nature and severity of the adverse event.
    • Document any contraindication to formulary alternatives.
    • Explain why alternatives would be ineffective, less effective, or associated with adverse effects.
    Denial Risk

    Initial Clinical Criteria Not Met

    Initial authorization is not supported when the member does not meet the required clinical criteria for gMG treatment with Zilbrysq.

    • AChR antibody is not positive.
    • MGFA clinical classification is outside II–IV.
    • MGADL total score is <6.
    • Required immunosuppressive-treatment failure or qualifying chronic plasmapheresis, PE, or IVIG history is not documented.
    • Inadequate response to a specified advanced therapy is not documented.
    Denial Risk

    Prohibited Concomitant Therapy

    Do not use Zilbrysq concomitantly for the same indication with eculizumab, Ultomiris, Rystiggo, Vyvgart, Vyvgart Hytrulo, IVIG, or rituximab. Concurrent use may result in denial of authorization.

    • Review the complete medication regimen before submitting the request.
    • Document discontinuation or lack of concurrent use of the listed therapies when applicable.
    Denial Risk

    Lack of Continued Response or Tolerability

    Continuation authorization may be denied when the member does not demonstrate ongoing benefit or cannot tolerate the current Zilbrysq regimen.

    • No positive clinical response is documented.
    • Unacceptable toxicity is present.
    • Disease progression is documented while on the current regimen.
    • Required continuation records are not submitted.
    Denial Risk

    Criteria Not Met

    Zilbrysq is considered not medically necessary when the member does not meet the applicable criteria described above.

    • This includes failure to meet initial gMG criteria, required treatment-failure criteria, advanced-therapy response requirements, continuation requirements, or applicable non-formulary exception requirements.
    MG-ADL threshold
    MeasureMyasthenia Gravis activities of daily living (MG-ADL) total score
    Minimum total scoreAt least 6 (≥6)
    Coverage applicationRequired as part of the initial generalized myasthenia gravis criteria